X4 Pharmaceuticals, Inc
XFOR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001501697
In the last 90 days, X4 Pharmaceuticals, Inc insiders filed 0 open-market purchases and 2 sales; 89 institutions reported holding it in 13F filings for Q2 2026, worth $463.0M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding X4 Pharmaceuticals, Inc changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 52 | 56 | +4 |
| Shares | 17.6M | 16.3M | −1.22M (−7.0%) |
| Value | $40.2M | $28.6M | −$11.6M (−28.9%) |
New holders (10)
Institutions that held X4 Pharmaceuticals, Inc at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Bank of New York Mellon Corp | 140,612 | $246.0K | 0.00% |
| Stifel Financial Corp | 69,599 | $122.0K | 0.00% |
| Minot Wealth Management LLC | 55,000 | $96.0K | 0.02% |
| Jane Street Group, LLC | 36,847 | $64.0K | 0.00% |
| Virtu Financial LLC | 25,965 | $45.0K | 0.00% |
| Dynamic Advisor Solutions LLC | 10,000 | $18.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 9,695 | $16.0K | 0.00% |
| Federation des caisses Desjardins du Quebec | 4,000 | $7.00K | 0.00% |
| Cubist Systematic Strategies, LLC | 1,400 | $2.00K | 0.00% |
| Federated Hermes, Inc. | 152 | – | – |
Sold out (6)
Institutions that held X4 Pharmaceuticals, Inc at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Acadian Asset Management LLC | 57,270 | $130.0K |
| FMR LLC | 53,031 | $121.0K |
| Goldman Sachs Group Inc | 20,949 | $48.0K |
| Connor, Clark & Lunn Investment Management Ltd. | 12,786 | $29.0K |
| Engineers Gate Manager LP | 11,874 | $27.0K |
| JPMorgan Chase & Co | 203 | $0 |